Go to
current issue
-
COVID-19 platform trial delivers Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-07 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
FDA rejects NASH drug Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-07 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
FDA rejects first DARPin Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-07 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Harnessing the PERx of covalent protein drugs Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-07 M. Teresa Villanueva
Discover the world’s best science and medicine | Nature.com
-
Targeting CD70 in acute myeloid leukaemia Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-06 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Inhibiting the HIV capsid protein Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-06 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
ASO rescues Pelizaeus-Merzbacher disease Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-06 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Selectively targeting pathogenic TH17 cells Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-07-06 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
RNA methyltransferase inhibitor reduces AML Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-29 Megan Cully
Discover the world’s best science and medicine | Nature.com
-
Two birds with one stone Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-26 Akila Sridhar
Discover the world’s best science and medicine | Nature.com
-
STK19: a new target for NRAS-driven cancer Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-25 Christopher R. M. Asquith; Louisa Temme
Discover the world’s best science and medicine | Nature.com
-
Driving CARs to clear senescent cells Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-24 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-17 Anwesha Dey,Xaralabos Varelas,Kun-Liang Guan
The Hippo pathway is an evolutionarily conserved signalling pathway with key roles in organ development, epithelial homeostasis, tissue regeneration, wound healing and immune modulation. Many of these roles are mediated by the transcriptional effectors YAP and TAZ, which direct gene expression via control of the TEAD family of transcription factors. Dysregulated Hippo pathway and YAP/TAZ–TEAD activity
-
Upcoming market catalysts in Q3 2020. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-16 Amber Eisold
Discover the world’s best science and medicine | Nature.com
-
Lidia Fonseca. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-16 Asher Mullard
Last year, Pfizer joined the growing ranks of pharmaceutical firms with a digital strategy leader on their executive management teams. Lidia Fonseca, Pfizer’s first Chief Digital & Technology Officer, stepped into this role with a broad remit to set the company’s digital goals in drug discovery and development, operational processes and manufacturing, product sales, patient-facing experiences and more
-
Immune status could determine efficacy of COVID-19 therapies. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-16 Megan Cully
Emerging evidence suggests that SARS-CoV-2 can drive a diverse array of immune processes, raising the risk that immunosuppressant agents that are in clinical trials might be effective for some patients but detrimental for others.
-
RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-11 Amanda R Moore,Scott C Rosenberg,Frank McCormick,Shiva Malek
RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in cancers, and, consequently, investigators have sought an effective RAS inhibitor for more than three decades. Even 10 years ago, RAS inhibitors were so elusive that RAS was termed ‘undruggable’. Now, with the success of allele-specific covalent inhibitors against the most frequently mutated version of RAS in non-small-cell lung
-
Reversing cerebrovascular dysfunction. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-08 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
COVID-19 vaccines start moving into advanced trials. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-08 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
First antibody against COVID-19 spike protein enters phase I. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-08 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Base editing rescues hearing in mice. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-08 M Teresa Villanueva
Discover the world’s best science and medicine | Nature.com
-
Using loss-of-function human mutations to evaluate drug targets. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-08 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Targeted degraders clear first safety hurdles. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-08 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Developing blockbuster drugs: both nature and nurture. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-08 Lotte Berghauser Pont,Jiri Keirsse,Rachel Moss,Pawel Poda,Lucas Robke,Stephan Wurzer
Discover the world’s best science and medicine | Nature.com
-
Transferrin' across the blood-brain barrier. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-05 Joseph Willson
Discover the world’s best science and medicine | Nature.com
-
Switching off MDSCs by targeting REL. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-06-05 Sarah Seton-Rogers
Discover the world’s best science and medicine | Nature.com
-
Rebalancing protein synthesis in fragile X syndrome Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-28 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
The quest to slow ageing through drug discovery. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-28 Linda Partridge,Matias Fuentealba,Brian K Kennedy
Although death is inevitable, individuals have long sought to alter the course of the ageing process. Indeed, ageing has proved to be modifiable; by intervening in biological systems, such as nutrient sensing, cellular senescence, the systemic environment and the gut microbiome, phenotypes of ageing can be slowed sufficiently to mitigate age-related functional decline. These interventions can also
-
Supporting a data-driven approach to regulatory intelligence. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-28 Andrew S Robertson,Alexis Reisin Miller,Felipe Dolz
Drug developers are increasingly applying data-driven analysis of the actions of regulatory agencies to gain insights into their expectations and applications of regulatory policy, but such strategies can be limited by the availability and quality of regulatory datasets. Here, we discuss how establishing a single, robust, accessible database of FDA regulatory actions could help address this limitation
-
Cancer cell therapies: the clinical trial landscape. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-26 Jia Xin Yu,Samik Upadhaya,Revati Tatake,Fern Barkalow,Vanessa M Hubbard-Lucey
Discover the world’s best science and medicine | Nature.com
-
Impact of COVID-19 on oncology clinical trials. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-18 Samik Upadhaya,Jia Xin Yu,Cristina Oliva,Megan Hooton,Jeffrey Hodge,Vanessa M Hubbard-Lucey
Discover the world’s best science and medicine | Nature.com
-
Jennifer Doudna. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-15 Asher Mullard
CRISPR–Cas gene editors are now both moving into the clinic and being embraced as a means to find and validate drug targets. But for Jennifer Doudna, who helped pioneer this promise with her work at UC Berkeley, the full potential of these tools will only be unleashed when they can be used at scale. To this end, Doudna and colleagues partnered last year with GlaxoSmithKline to launch the Laboratory
-
Gene-editing pipeline takes off. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-15 Asher Mullard
Clinical trials of genome-editing agents — including CRISPR–Cas9 editors, zinc finger nucleases and TALENs — are pushing ex vivo, immuno-oncology and in vivo treatment frontiers.
-
Remote digital monitoring in clinical trials in the time of COVID-19. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-14 Jennifer C Goldsack,Elena S Izmailova,Joseph P Menetski,Steven C Hoffmann,Peter M A Groenen,John A Wagner
Discover the world’s best science and medicine | Nature.com
-
KNa1.1 channels as a target for treating early-onset epilepsy. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-13 Zicheng Hu,Hannah N Gruner,Jana Gagacheva,Olga Gulyaeva
Discover the world’s best science and medicine | Nature.com
-
Digital technologies for medicines: shaping a framework for success. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-12 Francesca Cerreta,Armin Ritzhaupt,Thomas Metcalfe,Scott Askin,João Duarte,Michael Berntgen,Spiros Vamvakas
Regulatory agencies can provide advice to support developers of digital technologies for medicines use, but what are the best strategies to maximise the chance of a successful regulatory interaction? Here, EMA and industry representatives comment on the experience so far.
-
Hints of hope with remdesivir. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-11 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Parkinson disease setback. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-11 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
COVID umbrella trials multiply. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-11 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Selective stabilization supports phosphatase targeting in cancer. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-11 Joseph Willson
Discover the world’s best science and medicine | Nature.com
-
Targeting CDK12 to treat DM1. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-08 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Gasdermin D inhibitor protects against sepsis. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-08 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
TRAIL blockade improves heart function. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-08 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Shortening jet-lag recovery. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-08 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Tumours use NETs as physical shields. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-06 Alexandra Flemming
Discover the world’s best science and medicine | Nature.com
-
Publisher Correction: ASPI: a public-private partnership to develop treatments for autism. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-06 Seth Ness,Gahan Pandina,Shyla Jagannatha,Kyle Wathen,Abigail Bangerter,Nikolay V Manyakov,Robert Hendren,Bennett Leventhal,Declan Murphy,Geraldine Dawson,Wayne C Drevets,Husseini K Manji
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
10 years of biosimilars: lessons and trends. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-01 Irena Royzman,Khushbu Shah
Discover the world’s best science and medicine | Nature.com
-
A novel vaccine target for malaria. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-04-30 Katharine H Wrighton
Discover the world’s best science and medicine | Nature.com
-
What makes a drug discovery consortium successful? Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-04-29 Peter B Simpson,Graeme F Wilkinson
Consortia are enabling drug discovery in areas that individual organizations are unable to support alone because of the high risk or the need to pool information. This article discusses desirable features that can underpin the success of such consortia.
-
RNA therapeutics on the rise. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-04-27 Feng Wang,Travis Zuroske,Jonathan K Watts
Discover the world’s best science and medicine | Nature.com
-
Antibody intervention rescues mice from sepsis. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-04-22 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-04-20 Anneliene Hechtelt Jonker,Virginie Hivert,Michela Gabaldo,Liliana Batista,Daniel O'Connor,Annemieke Aartsma-Rus,Simon Day,Ken Sakushima,Diego Ardigo
The International Rare Diseases Research Consortium (IRDiRC) has created a Guidebook to facilitate drug development for rare diseases by organizing available tools into a standardized framework.
-
Industry shows increased appetite for macrophage biology. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-01 Chris Morrison
Macrophage-focused immuno-oncology programmes were in the doldrums just a year ago, but are now back on the move in the wake of Gilead Sciences’ US$4.9 billion acquisition of Forty Seven.
-
Breaking Eroom's Law. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-04-16 Michael S Ringel,Jack W Scannell,Mathias Baedeker,Ulrik Schulze
Discover the world’s best science and medicine | Nature.com
-
FDA new drug approvals in Q1 2020. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-01 Lisa Urquhart
Discover the world’s best science and medicine | Nature.com
-
PIP5K1A: a potential target for cancers with KRAS or TP53 mutations. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-04-24 Michael P East,Tuomo Laitinen,Christopher R M Asquith
Discover the world’s best science and medicine | Nature.com
-
John-Arne Røttingen. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-01 Asher Mullard
Over 180 clinical trials of proposed COVID-19 drugs are already recruiting patients, and another 150 are registered to start recruiting patients soon. But many of these trials are small and not designed to identify the best treatment strategies for the COVID-19 pandemic. For Chief Executive of the Research Council of Norway John-Arne Røttingen, a more collaborative approach is now needed. And as Chair
-
The COVID-19 vaccine development landscape. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-01 Tung Thanh Le,Zacharias Andreadakis,Arun Kumar,Raúl Gómez Román,Stig Tollefsen,Melanie Saville,Stephen Mayhew
Discover the world’s best science and medicine | Nature.com
-
Novel drug targets in 2019. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-01 Sorin Avram,Liliana Halip,Ramona Curpan,Tudor I Oprea
Discover the world’s best science and medicine | Nature.com
-
FDA relaxes cardiovascular trial requirements for diabetes drugs. Nat. Rev. Drug. Disc. (IF 64.797) Pub Date : 2020-05-01 Asher Mullard
Discover the world’s best science and medicine | Nature.com
京公网安备 11010802027423号